GB0819280D0 - Imgaing and radiotherapy methods - Google Patents

Imgaing and radiotherapy methods

Info

Publication number
GB0819280D0
GB0819280D0 GBGB0819280.9A GB0819280A GB0819280D0 GB 0819280 D0 GB0819280 D0 GB 0819280D0 GB 0819280 A GB0819280 A GB 0819280A GB 0819280 D0 GB0819280 D0 GB 0819280D0
Authority
GB
United Kingdom
Prior art keywords
imgaing
radiotherapy methods
radiotherapy
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0819280.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
General Electric Co
Original Assignee
GE Healthcare Ltd
General Electric Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd, General Electric Co filed Critical GE Healthcare Ltd
Priority to GBGB0819280.9A priority Critical patent/GB0819280D0/en
Publication of GB0819280D0 publication Critical patent/GB0819280D0/en
Priority to RU2011113996/15A priority patent/RU2011113996A/ru
Priority to PCT/US2009/061271 priority patent/WO2010048144A2/en
Priority to US13/124,703 priority patent/US20110286922A1/en
Priority to KR1020117008974A priority patent/KR20110074988A/ko
Priority to BRPI0919690A priority patent/BRPI0919690A2/pt
Priority to EP09749242A priority patent/EP2349351A2/en
Priority to MX2011004161A priority patent/MX2011004161A/es
Priority to AU2009307783A priority patent/AU2009307783A1/en
Priority to CN2009801423890A priority patent/CN102186505A/zh
Priority to CA2738955A priority patent/CA2738955A1/en
Priority to JP2011533266A priority patent/JP2012506439A/ja
Priority to US13/622,483 priority patent/US20130101509A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0819280.9A 2008-10-21 2008-10-21 Imgaing and radiotherapy methods Ceased GB0819280D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB0819280.9A GB0819280D0 (en) 2008-10-21 2008-10-21 Imgaing and radiotherapy methods
JP2011533266A JP2012506439A (ja) 2008-10-21 2009-10-20 イメージング及び放射線治療法
EP09749242A EP2349351A2 (en) 2008-10-21 2009-10-20 Imaging and radiotherapy methods
PCT/US2009/061271 WO2010048144A2 (en) 2008-10-21 2009-10-20 Imaging and radiotherapy methods
US13/124,703 US20110286922A1 (en) 2008-10-21 2009-10-20 Imaging and radiotherapy methods
KR1020117008974A KR20110074988A (ko) 2008-10-21 2009-10-20 영상화 및 방사선요법을 위한 방법
BRPI0919690A BRPI0919690A2 (pt) 2008-10-21 2009-10-20 métodos para detectar células-tronco de tumor em um paciente, para monitorar o efeito do tratamento de um tumor em um paciente, e para radioterapia em um paciente com câncer, formulaçõ farmacêutica, e, composto
RU2011113996/15A RU2011113996A (ru) 2008-10-21 2009-10-20 Способы визуализации и радиотерапии
MX2011004161A MX2011004161A (es) 2008-10-21 2009-10-20 Generacion de imagenes y metodos de radioterapia.
AU2009307783A AU2009307783A1 (en) 2008-10-21 2009-10-20 Imaging and radiotherapy methods
CN2009801423890A CN102186505A (zh) 2008-10-21 2009-10-20 成像和放射治疗方法
CA2738955A CA2738955A1 (en) 2008-10-21 2009-10-20 Imaging and radiotherapy methods
US13/622,483 US20130101509A1 (en) 2008-10-21 2012-09-19 Imaging and radiotherapy methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0819280.9A GB0819280D0 (en) 2008-10-21 2008-10-21 Imgaing and radiotherapy methods

Publications (1)

Publication Number Publication Date
GB0819280D0 true GB0819280D0 (en) 2008-11-26

Family

ID=40097766

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0819280.9A Ceased GB0819280D0 (en) 2008-10-21 2008-10-21 Imgaing and radiotherapy methods

Country Status (12)

Country Link
US (1) US20110286922A1 (enExample)
EP (1) EP2349351A2 (enExample)
JP (1) JP2012506439A (enExample)
KR (1) KR20110074988A (enExample)
CN (1) CN102186505A (enExample)
AU (1) AU2009307783A1 (enExample)
BR (1) BRPI0919690A2 (enExample)
CA (1) CA2738955A1 (enExample)
GB (1) GB0819280D0 (enExample)
MX (1) MX2011004161A (enExample)
RU (1) RU2011113996A (enExample)
WO (1) WO2010048144A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1729824T3 (da) 2004-03-02 2009-11-02 Cellectar Inc Phospholipidanaloger til behandling af cancere
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
CU23844B1 (es) * 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
RU2012100765A (ru) * 2009-06-12 2013-07-20 Селлектар, Инк. Эфирные и алкильные фосфолипидные производные для лечения рака и визуализации и детектирования раковых стволовых клеток
CN102725003A (zh) * 2009-12-22 2012-10-10 通用电气健康护理有限公司 用于癌症干细胞中的人体肝脏醛脱氢酶进行体内成像的醛类化合物
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
WO2013012754A1 (en) * 2011-07-15 2013-01-24 University Of Southern California Boron-based dual imaging probes, compositions and methods for rapid aqueous f-18 labeling, and imaging methods using same
WO2013048832A1 (en) * 2011-09-29 2013-04-04 Ge Healthcare Limited 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
WO2013048811A1 (en) * 2011-09-30 2013-04-04 Ge Healthcare Limited Imaging and radiotherapy methods for tumour stem cells
US8927732B2 (en) * 2012-03-30 2015-01-06 General Electric Company Biotin stannane for HPLC-free radioiodination
WO2014145493A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Radioactive substrates for aldehyde dehydrogenase
WO2017187717A1 (ja) * 2016-04-28 2017-11-02 国立大学法人名古屋大学 蛍光プローブ、蛍光検出方法及び蛍光プローブの使用方法
FR3054564B1 (fr) * 2016-07-28 2018-08-31 Advanced Biodesign Substrat specifique d'une isoenzyme de l'aldh
KR101941223B1 (ko) * 2017-04-04 2019-01-22 을지대학교 산학협력단 복강경 수술용 삼중 융합영상장치
JP2023025307A (ja) * 2020-01-31 2023-02-22 国立大学法人 東京大学 アルデヒドロゲナーゼ１ａ１検出用青色蛍光プローブ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876956A (en) * 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
AU2003228744A1 (en) * 2002-04-29 2003-11-17 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
GB0502277D0 (en) * 2005-02-04 2005-03-09 Amersham Plc Novel imaging agents
US20080058316A1 (en) * 2006-02-27 2008-03-06 The Johns Hopkins University Cancer treatment with gama-secretase inhibitors
US20080187938A1 (en) * 2006-09-22 2008-08-07 The Regents Of The University Of Michigan ALDH1 As A Cancer Stem Cell Marker

Also Published As

Publication number Publication date
JP2012506439A (ja) 2012-03-15
WO2010048144A2 (en) 2010-04-29
KR20110074988A (ko) 2011-07-05
CN102186505A (zh) 2011-09-14
CA2738955A1 (en) 2010-04-29
WO2010048144A3 (en) 2010-07-22
BRPI0919690A2 (pt) 2015-12-08
AU2009307783A1 (en) 2010-04-29
US20110286922A1 (en) 2011-11-24
EP2349351A2 (en) 2011-08-03
MX2011004161A (es) 2011-06-06
RU2011113996A (ru) 2012-11-27

Similar Documents

Publication Publication Date Title
GB0819280D0 (en) Imgaing and radiotherapy methods
PT2308885E (pt) Novos compostos e métodos para terapia
IL206654A0 (en) Combination therapy
IL210804A (en) Benzylidenehydrazides and their uses
GB0808973D0 (en) Radiotherapy apparatus
GB0808575D0 (en) Compilign and linking
GB0807018D0 (en) Antibodies and treatment
GB0806569D0 (en) Methods
GB0803477D0 (en) Therapy selection method
GB0816501D0 (en) Photo-ionic pacemakers
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
IL213321A0 (en) Descenting systems and methods
ZA201103456B (en) Leukolectins and uses thereof
EP2247601A4 (en) THIAZOPYRIMIDINONE AND APPLICATIONS THEREOF
GB0823333D0 (en) Apparatus and methods
GB0912744D0 (en) Methods and uses
EP2470022A4 (en) COMPOUNDS AND METHODS
IL205308A0 (en) Compounds and methods
GB0823408D0 (en) Apparatus and methods
GB0909380D0 (en) Method and use
GB0803948D0 (en) Combination therapy
GB0813359D0 (en) Halfin and/or platerfin
GB0803082D0 (en) Method and kit
GB0707069D0 (en) Methods and uses
GB0813352D0 (en) Cancer treatment and test

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)